←
Darsh Patel767 posts
Darsh Patel avatar

Darsh Patel

@darsh_cp

investor @_DimensionCap

◷ Joined September 2014▧ 24 Photos and videos
Nan Li avatar
⟳ Darsh Patel retweeted
Nan Li@nanli·19h

Excited to announce @_DimensionCap’s partnership with @changhiskhan, @eddyxu and the team at @lancedb! Lance has built the leading database for large scale, multimodal data. This data workload is increasingly common in large scale AI training and some of the top research groups working on frontier models, world models, robotics, etc have switched over to LanceDB. Excited for the journey ahead, more soon!

The next generation of models needs a data stack built for AI. We just raised a $57.5M Series B to help researchers turn petabytes of video, images, and audio into better models, faster. Read the announcement: lancedb.com/blog/lancedb-ser…

2:53
LanceDB avatar
⟳ Darsh Patel retweeted
LanceDB@lancedb·21h

The next generation of models needs a data stack built for AI. We just raised a $57.5M Series B to help researchers turn petabytes of video, images, and audio into better models, faster. Read the announcement: lancedb.com/blog/lancedb-ser…

2:53
Nikhil Namburi avatar
⟳ Darsh Patel retweeted
Nikhil Namburi@nikhilvnamburi·19h

The world is multi-modal. Your data warehouse should be too! I’ve been a happy user of @lancedb since 2024, it’s a magical experience. Turns out your favorite AI labs agree :) Honored to partner with @changhiskhan @eddyxu

The next generation of models needs a data stack built for AI. We just raised a $57.5M Series B to help researchers turn petabytes of video, images, and audio into better models, faster. Read the announcement: lancedb.com/blog/lancedb-ser…

2:53
Joshua Meier avatar
⟳ Darsh Patel retweeted
Joshua Meier@joshim5·Nov 5

Today we’re announcing a collaboration with @Roche, a leader in AI-driven drug discovery. Roche will apply @chaidiscovery's platform to help accelerate discovery programs across a number of targets in its therapeutic areas.

0:09
Zavain Dar avatar
⟳ Darsh Patel retweeted
Zavain Dar@zavaindar·Nov 3

this is not surprising and entirely predictable. long term moats in semi will now come from those with supply chain relationships and access. like software and mathematics, the “design” element, will asymptotically commoditize

Darsh Patel avatar
Darsh Patel@darsh_cp·Oct 30

for halloween i’m going to be an autonomy analyst that pitches opening a $vicr position for the robot torso exposure

Darsh Patel avatar
Darsh Patel@darsh_cp·Oct 29

end state of the world josh kushner owns your intelligence and your sports teams, with the added benefit that he watches you while you sleep

Today, we are announcing an agreement to acquire ADT. Home security has the qualities we look for in the businesses we own: an essential service built on specialist expertise and earned trust. We see an opportunity to build on that foundation for decades, investing in its people and technology to deliver the best outcomes for customers. Our ambition is to help ADT define the next era of trusted home security. thriveholdings.com/thrive-ho…

Sajith Wickramasekara avatar
⟳ Darsh Patel retweeted
Sajith Wickramasekara@sajithw·Oct 28

I tell everyone that @divergence_labs is one of the most impressive early stage biotech teams. Excited to see them start telling their story.

Today, in collaboration with Anthropic, we’re excited to share rapid initial progress towards an antibody treatment for food allergy, which affects over 200 million people worldwide, discovered with the help of Claude. At Divergence Labs, we believe that AI can unlock the next generation of antibody therapeutics with more effective mechanisms than before. Such mechanisms are urgently needed in food allergy, which involve overcoming one of the tightest affinity protein pairs in immunology, IgE and its receptor FcεRI, on mast cells. Treatment with Xolair—the only approved antibody for food allergy—sequesters circulating IgE, but mast cells remain sensitized for weeks to months due to the extraordinarily slow dissociation of IgE from FcεRI. We envision a treatment that actively pulls IgE off of FcεRI, without waiting for natural dissociation. Like picking a lock, this requires the right combination of geometry and force. Our research team, working with Claude, ideated on mechanisms to accomplish this disruption, and converged on an antibody format with two arms with different functions and epitopes. Within one month, we designed, synthesized, and experimentally confirmed the biophysical function of the two arms, which we are now assembling into full therapeutic formats.

0:15
Darsh Patel avatar
Darsh Patel@darsh_cp·Oct 28

incredibly privileged to learn from @SimonDBarnett, @bauer_lesavage, and @ChemVagabond every day, and thankful that they regularly open-source their insights for the rest of the ecosystem to learn from. here's to the third of many

That's a wrap! Today, we're (@_DimensionCap) releasing the third volume of our Research Magazine. Before anything else, I want to shout out my tremendous research colleagues Bauer (@bauer_lesavage) and Frank (@ChemVagabond), who were both core contributors to this volume. We're also releasing a digital version: dimensioncap.com/research-ma… ~~~ Compared to previous magazines, our third work is more heavily focused on machine learning. That's by design. Dimension invests in all companies, small and large, spanning the continuum from compute to the life sciences. At our core, we love technical teams working on the hardest, most important problems. That means data center infrastructure, new networking protocols, new silicon, inference optimization, physical AI, lean/tech-enabled biotechs, data generation, and more. As such, we challenged ourselves to go deeper into the compute stack than ever before, and how it connects to various branches of science. This magazine is a small sliver of the proverbial 'research exhaust' that our team generates over the course of a few quarters. ~~~ One piece I want to highlight is Without Form and Void, which was my attempt at unifying my background in fluid mechanics, my admiration of clever inductive biases in ML, and a major industry chokepoint seldom talked about in CS circles, which is bioprocess scaling. It's also the first piece I've tried writing with this much history (back to Galileo). ~~~ We hope you like Vol. 3 and we can't wait to show you all what's in store in Vol. 4!

Post attachmentPost attachment
Simon Barnett avatar
⟳ Darsh Patel retweeted
Simon Barnett@SimonDBarnett·Oct 28

That's a wrap! Today, we're (@_DimensionCap) releasing the third volume of our Research Magazine. Before anything else, I want to shout out my tremendous research colleagues Bauer (@bauer_lesavage) and Frank (@ChemVagabond), who were both core contributors to this volume. We're also releasing a digital version: dimensioncap.com/research-ma… ~~~ Compared to previous magazines, our third work is more heavily focused on machine learning. That's by design. Dimension invests in all companies, small and large, spanning the continuum from compute to the life sciences. At our core, we love technical teams working on the hardest, most important problems. That means data center infrastructure, new networking protocols, new silicon, inference optimization, physical AI, lean/tech-enabled biotechs, data generation, and more. As such, we challenged ourselves to go deeper into the compute stack than ever before, and how it connects to various branches of science. This magazine is a small sliver of the proverbial 'research exhaust' that our team generates over the course of a few quarters. ~~~ One piece I want to highlight is Without Form and Void, which was my attempt at unifying my background in fluid mechanics, my admiration of clever inductive biases in ML, and a major industry chokepoint seldom talked about in CS circles, which is bioprocess scaling. It's also the first piece I've tried writing with this much history (back to Galileo). ~~~ We hope you like Vol. 3 and we can't wait to show you all what's in store in Vol. 4!

Post attachmentPost attachment
Darsh Patel avatar
Darsh Patel@darsh_cp·Oct 28

in few years time, we’ll look back and laugh at how inefficiently we used to develop new medicines. special shoutout to dimension portfolio company divergence labs that we’ve had the privilege of watching up close these past few months

Post attachment

Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences. anthropic.com/research/early…

Zavain Dar avatar
⟳ Darsh Patel retweeted
Zavain Dar@zavaindar·Oct 28

awesome to see 2 @_DimensionCap partnered companies charging to upend the future of medicine featured here!! 1: @enveda (Dimension led Series B) 2: Divergence Labs (Dimension cofounded neo biotech) *the future is extremely bright*

Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences. anthropic.com/research/early…

Anthropic avatar
⟳ Darsh Patel retweeted
Anthropic@AnthropicAI·Oct 27

Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences. anthropic.com/research/early…

Darsh Patel avatar
Darsh Patel@darsh_cp·Oct 26

if you say "contrary to popular belief, modal is not an inference provider. they're a serverless gpu cloud that happens to make some money on inference" three times in the mirror, @nikhilvnamburi appears behind you